AllCells opens new Boston blood tissue site

AllCells is to build a new hematologic tissue collection site in Boston as it looks to expand its offering to life science firms.

The clinic, which should be up and running by November, is aimed to “enhance service to life science researchers located throughout US east coast, Europe, and rest of world,” according to a statement from AllCells.

The company focuses on manufacturing fresh hematologic tissue, which includes whole bone marrow, Leukapheresis products, and whole peripheral blood, all of which is sourced from healthy human donors.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Its latest clinic is set up to “mobilize” healthy donor volunteers using treatments such as Amgen’s Neupogen (filgrastim) and/or Sanofi’s Mozobil (plerixafor) to boost hematopoietic stem cell movement into certain areas of the blood, so it can be collected or packaged later on.

AllCells-Boston, as it has been dubbed, could also increase its offering in the future to purify and cryopreserve certain primary cell types for in-vitro research, and is also set to work on new products around gene therapies. This builds on its first U.S. site in Alameda, CA.

AllCells’ president and CEO, Jay Tong, said: “Our customers depend on these hematology and immunology primary cell products to support their cell-based assay applications in drug discovery and preclinical development work-flows. AllCells-Boston strengthens our business continuity capability enabling us to fill customer orders from two different clinical collection sites.

“The second site expands the company’s overall donor repository thereby providing customers access to a larger and more diverse human donor pool for procuring relevant phenotypes important for their specific cell-based assay applications. The placement of our tissue collection facilities in Boston, MA together with current Alameda, CA, facilities helps assure customers will receive fresh products having the highest possible cell viability.”

- check out the release


Suggested Articles

Bayer CEO Werner Baumann stressed “less and less trust in society" for technology advances as a hurdle for pharma companies working on gene editing.

As GlaxoSmithKline looks to start a 23andMe-partnered test this year, the Big Pharma is increasingly looking to tech for its R&D.

LabCorp has unveiled a new suite of cell and gene therapy development offerings from Covance as it looks to get into this burgeoning area.